First atypical case of 2019 novel coronavirus in Yan'an, China

Hao, Wendong; Li, Manxiang; Huang, Xiaoqi

doi:10.1016/j.cmi.2020.02.011

Cited by 19 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the literature and research, there has been very few documented reports of an atypical presentation of the novel coronavirus. In a case report conducted by Hao et al, a 60-year-old gentleman presented with fatigue but was afebrile along with no lower respiratory tract symptoms [5]. Upon workup for fatigue, CT chest findings demonstrated a patchy high-density shadow in bilateral lungs that gradually improved with time.…”

Section: Discussionmentioning

confidence: 96%

Novel Coronavirus (2019-nCoV) in Disguise

Zhang¹,

Douglas²,

Abideen³

et al. 2020

Cureus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Novel Coronavirus (2019-nCoV) in Disguise

Zhang¹,

Douglas²,

Abideen³

et al. 2020

Cureus

View full text Add to dashboard Cite

“…Atypical clinical manifestations have also been reported in COVID-19 in which the only reporting symptom was fatigue. Such patients may lack respiratory signs, such as fever, cough, and sputum ( 83 ). Hence, the clinicians must be on the look-out for the possible occurrence of atypical clinical manifestations to avoid the possibility of missed diagnosis.…”

Section: Current Worldwide Scenario Of Sars-cov-2mentioning

confidence: 99%

Coronavirus Disease 2019–COVID-19

et al. 2020

View full text Add to dashboard Cite

SUMMARY In recent decades, several new diseases have emerged in different geographical areas, with pathogens including Ebola virus, Zika virus, Nipah virus, and coronaviruses (CoVs). Recently, a new type of viral infection emerged in Wuhan City, China, and initial genomic sequencing data of this virus do not match with previously sequenced CoVs, suggesting a novel CoV strain (2019-nCoV), which has now been termed severe acute respiratory syndrome CoV-2 (SARS-CoV-2). Although coronavirus disease 2019 (COVID-19) is suspected to originate from an animal host (zoonotic origin) followed by human-to-human transmission, the possibility of other routes should not be ruled out. Compared to diseases caused by previously known human CoVs, COVID-19 shows less severe pathogenesis but higher transmission competence, as is evident from the continuously increasing number of confirmed cases globally. Compared to other emerging viruses, such as Ebola virus, avian H7N9, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has shown relatively low pathogenicity and moderate transmissibility. Codon usage studies suggest that this novel virus has been transferred from an animal source, such as bats. Early diagnosis by real-time PCR and next-generation sequencing has facilitated the identification of the pathogen at an early stage. Since no antiviral drug or vaccine exists to treat or prevent SARS-CoV-2, potential therapeutic strategies that are currently being evaluated predominantly stem from previous experience with treating SARS-CoV, MERS-CoV, and other emerging viral diseases. In this review, we address epidemiological, diagnostic, clinical, and therapeutic aspects, including perspectives of vaccines and preventive measures that have already been globally recommended to counter this pandemic virus.

show abstract

“…His real-time RT-PCR throat swab was negative for COVID-19 on two follow up assessments. The patient was categorised as a mild COVID-19 and was recovered in 4 days ( 8 ).…”

Section: Reported Cases With Travel Historymentioning

confidence: 99%

How the first cases of COVID-19 in 10 countries become infected? A case series

Sadeghmoghadam¹,

Daneshfar²,

Sharifi³

et al. 2023

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Recently, a new respiratory infectious disease called COVID-19 has emerged and created a global emergency. It was initially linked to the animal-to-human transmission. However, it is now thought that COVID-19 is spreading through human-to-human transmission mainly via droplets. As there is no definite antiviral therapy for the treatment of cases with COVID-19 the best option for slowing down the pandemic and reducing mortality rates is protection against the virus of interest. To achieve this goal obtaining information about how first cases infected with COVID-19 is crucial. Hence, this study aims to review the studies published in peer-reviewed journals to report the first confirmed cases with COVID-19. Herein, we review the origin, symptoms, diagnostic tests, and progress of the disease and possible actions of authorities which would be effective in similar pandemics in the future. This study reviewed 13 cases (5 females and 8 males; 25-61 years old) from 10 countries. All cases have recovered from COVID-19. The results of this review suggested that timely reports of the confirmed cases, notifying World Health Organization and providing information to the general population about the methods of spreading the virus would have decreased the number of infected cases and mortality rates. In addition, the travel history of the first confirmed cases in various countries suggested that prompt actions in restricting travels and closing borders could be an efficient strategy in preventing the transmission of the disease outside of the affected sites. Efforts should be taken by health authorities for preparing the world for future epidemic/pandemic in terms of developing advanced screening strategies in the borders and diagnostic strategies for early identification of infected cases.

show abstract

First atypical case of 2019 novel coronavirus in Yan'an, China

Cited by 19 publications

References 3 publications

Novel Coronavirus (2019-nCoV) in Disguise

Novel Coronavirus (2019-nCoV) in Disguise

Coronavirus Disease 2019–COVID-19

How the first cases of COVID-19 in 10 countries become infected? A case series

Contact Info

Product

Resources

About